LeonaBio CEO Litton sells $27,687 in shares
#LeonaBio #CEO #Litton #stock sale #shares #regulatory filing #executive transaction
📌 Key Takeaways
- LeonaBio CEO Litton sold $27,687 worth of company shares
- The sale was disclosed in a recent regulatory filing
- It represents a routine transaction by an executive
- The sale amount is relatively small for a CEO transaction
🏷️ Themes
Executive Trading, Corporate Disclosure
📚 Related People & Topics
Chief executive officer
Highest-ranking officer of an organization
A chief executive officer (CEO), also known as a chief executive or managing director, is the top-ranking corporate officer charged with the management of a company or a nonprofit organization. CEOs find roles in various organizations, including public and private corporations, nonprofit organizatio...
Entity Intersection Graph
Connections for Chief executive officer:
🌐
SEC filing
4 shared
👤
Jay Graber
3 shared
🌐
Bluesky
3 shared
🏢
Chief financial officer
3 shared
👤
Sundar Pichai
2 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) LeonaBio CEO Litton sells $27,687 in shares By Insider Trading Published 03/05/2026, 07:46 PM LeonaBio CEO Litton sells $27,687 in shares 0 LONA -10.20% LeonaBio, Inc. (NASDAQ:LONA) President and CEO Mark James Litton sold 5,156 shares of common stock on March 4, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted-average price of $5.37, for a total value of $27,687. Prices for the shares sold ranged from $5.03 to $5.70. The insider sale comes as the stock has delivered a 71% return over the past year, though shares remain highly volatile with a beta of 2.76. On March 3, Litton also exercised options on 22,254 shares of LeonaBio , Inc. common stock with a transaction price of $0. Following the sale, Litton directly owns 57,926 shares of LeonaBio, Inc. common stock. Litton also indirectly owns 656 shares each through Irrevocable Trusts of OSL, SWL and WGL. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access 13 additional InvestingPro Tips and comprehensive analysis through the platform’s Pro Research Report, available for LONA and 1,400+ other US stocks. In other recent news, LeonaBio Inc. has been making significant strides following its rebranding from Athira Pharma. The company has acquired global rights to develop and commercialize lasofoxifene, a Phase 3 drug candidate for metastatic breast cancer, with the exception of Asia and certain Middle Eastern countries. This strategic move was supported by a $90 million upfront private placement, with the potential for an addit...
Read full article at source